RQ Bio raised $115 million in a Series A to advance RQB01, a preclinical antibody program designed for broad, long-lasting seasonal influenza prevention. The company is targeting a “differentiated dual mechanism” against conserved viral components and claims that a single dose could provide protective effects persisting across a full season. Frazier Life Sciences led the round, with LifeArc Ventures participating alongside Forbion and EQT Life Sciences. RQ Bio said the candidate is currently in IND-enabling work and plans to bring RQB01 into clinical testing next year. The funding underscores renewed interest in non-vaccine prophylaxis for influenza, particularly for vulnerable populations and situations where standard preventive shots may be less feasible. (Article references: RQ Bio Series A and program reporting.)